AnaptysBio Inc

NASDAQ:ANABUnited States

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.

Contact Information

Headquarters

10770 WATERIDGE CIRCLE, SUITE 210SAN DIEGO, CA, United States 92121

Phone

858-362-6295

Fax

858-362-6296

Executives

Chairman of the Board

John Orwin

President, Chief Executive Officer, Director

Daniel Faga

Chief Financial Officer

Dennis Mulroy

Chief Operating Officer, General Counsel

Eric Loumeau

Chief Medical Officer

Paul Lizzul